IRIS
BUTTARI, FABIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 15.697
AS - Asia 3.124
EU - Europa 2.401
SA - Sud America 454
Continente sconosciuto - Info sul continente non disponibili 408
AF - Africa 53
OC - Oceania 10
Totale 22.147
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 15.510
SG - Singapore 1.361
IT - Italia 756
CN - Cina 511
BR - Brasile 377
RU - Federazione Russa 353
HK - Hong Kong 273
VN - Vietnam 258
KR - Corea 243
IE - Irlanda 227
DE - Germania 211
BD - Bangladesh 147
FR - Francia 141
UA - Ucraina 137
GB - Regno Unito 129
CA - Canada 95
JP - Giappone 88
FI - Finlandia 80
PL - Polonia 77
NL - Olanda 63
SE - Svezia 55
IN - India 42
ID - Indonesia 29
AR - Argentina 25
AT - Austria 24
TR - Turchia 24
BE - Belgio 23
IQ - Iraq 22
ES - Italia 21
CZ - Repubblica Ceca 20
CO - Colombia 19
ZA - Sudafrica 19
CR - Costa Rica 17
PH - Filippine 16
UZ - Uzbekistan 16
NI - Nicaragua 13
RO - Romania 12
MY - Malesia 11
CW - ???statistics.table.value.countryCode.CW??? 10
MX - Messico 10
PK - Pakistan 10
SV - El Salvador 10
CL - Cile 9
DK - Danimarca 9
EC - Ecuador 9
RS - Serbia 9
SA - Arabia Saudita 9
CH - Svizzera 8
EU - Europa 8
GR - Grecia 8
LT - Lituania 8
MA - Marocco 8
NG - Nigeria 8
AU - Australia 7
GT - Guatemala 7
HN - Honduras 7
AL - Albania 6
IL - Israele 6
IR - Iran 6
JM - Giamaica 6
PY - Paraguay 6
AE - Emirati Arabi Uniti 5
EE - Estonia 5
HR - Croazia 5
KE - Kenya 5
TT - Trinidad e Tobago 5
DM - Dominica 4
KG - Kirghizistan 4
KZ - Kazakistan 4
NO - Norvegia 4
NP - Nepal 4
OM - Oman 4
TH - Thailandia 4
UY - Uruguay 4
BN - Brunei Darussalam 3
CY - Cipro 3
DO - Repubblica Dominicana 3
EG - Egitto 3
GP - Guadalupe 3
PT - Portogallo 3
TN - Tunisia 3
TW - Taiwan 3
AZ - Azerbaigian 2
BZ - Belize 2
CG - Congo 2
DZ - Algeria 2
JO - Giordania 2
KW - Kuwait 2
LA - Repubblica Popolare Democratica del Laos 2
LB - Libano 2
MM - Myanmar 2
PR - Porto Rico 2
QA - Qatar 2
SI - Slovenia 2
VE - Venezuela 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
AO - Angola 1
BG - Bulgaria 1
BH - Bahrain 1
Totale 21.741
Salva come PNG Salva come JPEG
Città #
Wilmington 3.414
Houston 3.147
Woodbridge 2.637
Singapore 790
Ashburn 586
Chandler 527
Fairfield 487
San Jose 431
Ann Arbor 279
Hong Kong 250
New York 212
Rome 203
Dublin 199
Seattle 197
Dallas 191
Beijing 181
Cambridge 161
The Dalles 158
Council Bluffs 156
Santa Clara 136
Medford 129
Los Angeles 106
Jacksonville 93
Ho Chi Minh City 88
Tokyo 81
Dearborn 79
Buffalo 66
Lawrence 62
Hanoi 59
Lauterbourg 58
Munich 54
Kraków 51
São Paulo 50
North Bergen 46
Milan 45
Moscow 44
Zhengzhou 43
Chicago 32
Denver 30
Naples 30
London 29
Brooklyn 27
Philadelphia 27
Lappeenranta 26
Orem 26
San Diego 25
Norwalk 24
Palo Alto 24
Brussels 23
Warsaw 23
Atlanta 22
Carrboro 22
Toronto 22
Helsinki 21
Columbus 19
Redondo Beach 19
Southern 19
Jakarta 18
Chennai 17
Montreal 17
Boston 16
Brno 16
Frankfurt am Main 16
Seoul 16
Johannesburg 15
Menlo Park 15
Redwood City 15
Colorado Springs 14
San José 14
Amsterdam 13
Bologna 13
Managua 13
Phoenix 13
Roebling 13
Tampa 13
Arosio 12
Nanjing 12
Palermo 12
Rio de Janeiro 12
San Francisco 12
Detroit 11
Nuremberg 11
Stockholm 11
Elk Grove Village 10
Paris 10
Turin 10
Willemstad 10
Belo Horizonte 9
Guangzhou 9
Jackson 9
Salt Lake City 9
San Salvador 9
Ankara 8
Belgrade 8
Bogotá 8
Center 8
Falls Church 8
Hefei 8
Inverigo 8
Perugia 8
Totale 16.495
Salva come PNG Salva come JPEG
Nome #
Neurophysiology of synaptic functioning in multiple sclerosis 586
miR-142-3p Is a Key Regulator of IL-1β-Dependent Synaptopathy in Neuroinflammation 542
Tumor necrosis factor is elevated in progressive multiple sclerosis and causes excitotoxic neurodegeneration 532
No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML 530
TRPV1 polymorphisms and risk of interferon β-induced flu-like syndrome in patients with relapsing-remitting multiple sclerosis 520
Growth factors and synaptic plasticity in relapsing-remitting multiple sclerosis 509
Abnormal cervical lymph nodes in multiple sclerosis: a preliminary ultrasound study 508
Natalizumab discontinuation in patients with multiple sclerosis: Profiling risk and benefits at therapeutic crossroads 494
Cerebrospinal fluid detection of interleukin-1beta in phase of remission predicts disease progression in multiple sclerosis 488
Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naïve patients with multiple sclerosis 482
Determination of κFLC and κ Index in cerebrospinal fluid: a valid alternative to assess intrathecal immunoglobulin synthesis 481
Diagnostic tools for assessment of urinary dysfunction in MS patients without urinary disturbances 476
Interleukin-1β causes excitotoxic neurodegeneration and multiple sclerosis disease progression by activating the apoptotic protein p53 474
CB1 receptor affects cortical plasticity and response to physiotherapy in multiple sclerosis 467
Fingolimod reduces the clinical expression of active demyelinating lesions in MS 462
Nerve growth factor is elevated in the CSF of patients with multiple sclerosis and central neuropathic pain 445
Epstein-Barr virus genetic variants are associated with multiple sclerosis 440
From High- to Low-Frequency Administered Interferon-Beta for Multiple Sclerosis: A Multicenter Study 421
Association between a genetic variant of type-1 cannabinoid receptor and inflammatory neurodegeneration in multiple sclerosis 420
Treatment options to reduce disease activity after natalizumab: paradoxical effects of corticosteroids 413
Peripheral B cell depletion and central proinflammatory cytokine reduction following repeated intrathecal administration of rituximab in progressive Multiple Sclerosis 411
Prevalence of multiple sclerosis in the Lazio region, Italy: use of an algorithm based on health information systems 408
Reversible hyporegenerative anemia during natalizumab treatment 397
Delayed treatment of MS is associated with high CSF levels of IL-6 and IL-8 and worse future disease course 381
Remodeling functional connectivity in multiple sclerosis: A challenging therapeutic approach 374
Dimethyl fumarate vs. fingolimod in multiple sclerosis: an independent, multi-centre, real world, quasi-randomized study 359
Fingolimod reduces the clinical expression of active demyelinating lesions in MS 343
Tumor Necrosis Factor and Interleukin-1β Modulate Synaptic Plasticity during Neuroinflammation 336
Platelet-derived growth factor predicts prolonged relapse-free period in multiple sclerosis 334
Transient Receptor Potential Vanilloid 1 Modulates Central Inflammation in Multiple Sclerosis 328
Oral D-Aspartate enhances synaptic plasticity reserve in progressive multiple sclerosis 310
The Prevalence of Multiple Sclerosis in the Metropolitan Area of Rome: A Capture-Recapture Analysis 307
Interplay Between Age and Neuroinflammation in Multiple Sclerosis: Effects on Motor and Cognitive Functions 291
Exploiting the multifaceted effects of cannabinoids on mood to boost their therapeutic use against anxiety and depression 277
Treatment with Dimethyl Fumarate Enhances Cholinergic Transmission in Multiple Sclerosis 230
Prototypical proinflammatory cytokine (IL-1) in multiple sclerosis: role in pathogenesis and therapeutic targeting 210
Peripheral T cells from multiple sclerosis patients trigger synaptotoxic alterations in central neurons 210
Cerebrospinal fluid lactate is associated with multiple sclerosis disease progression 203
MiR-142-3p is a Critical Modulator of TNF-mediated Neuronal Toxicity in Multiple Sclerosis 197
Exercise protects from hippocampal inflammation and neurodegeneration in experimental autoimmune encephalomyelitis 191
Multiple Sclerosis: kFLC index values related to gender 187
Inflammation-Associated Synaptic Alterations as Shared Threads in Depression and Multiple Sclerosis 185
Emerging Role of Extracellular Vesicles in the Pathophysiology of Multiple Sclerosis 180
Modeling Resilience to Damage in Multiple Sclerosis: Plasticity Meets Connectivity 179
Re-Examining the Role of TNF in MS Pathogenesis and Therapy 165
Cerebrospinal fluid levels of L-glutamate signal central inflammatory neurodegeneration in multiple sclerosis 160
Cerebrospinal fluid inflammatory biomarkers predicting interferon-beta response in MS patients 158
IL-6 in the Cerebrospinal Fluid Signals Disease Activity in Multiple Sclerosis 155
Central Modulation of Selective Sphingosine-1-Phosphate Receptor 1 Ameliorates Experimental Multiple Sclerosis 151
MiR-142-3p regulates synaptopathy-driven disease progression in multiple sclerosis 143
Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study 142
The BDNF Val66Met Polymorphism (rs6265) Modulates Inflammation and Neurodegeneration in the Early Phases of Multiple Sclerosis 142
A novel POLR3A genotype leads to leukodystrophy type-7 in two siblings with unusually late age of onset 138
Re-emergence of T lymphocyte-mediated synaptopathy in progressive multiple sclerosis 133
Interleukin-9 protects from microglia- and TNF-mediated synaptotoxicity in experimental multiple sclerosis 130
Signals of pseudo-starvation unveil the amino acid transporter SLC7A11 as key determinant in the control of Treg cell proliferative potential 129
Corrigendum: Inflammation-Associated Synaptic Alterations as Shared Threads in Depression and Multiple Sclerosis 128
Low-contrast visual acuity test is associated with central inflammation and predicts disability development in newly diagnosed multiple sclerosis patients 124
Cerebrospinal fluid, brain, and spinal cord levels of L-aspartate signal excitatory neurotransmission abnormalities in multiple sclerosis patients and experimental autoimmune encephalomyelitis mouse model 123
A single nucleotide ADA genetic variant is associated to central inflammation and clinical presentation in MS: implications for cladribine treatment 122
Physical exercise and synaptic protection in human and pre-clinical models of multiple sclerosis 120
Age at disease onset associates with oxidative stress, neuroinflammation, and impaired synaptic plasticity in relapsing-remitting multiple sclerosis 120
A large family with p.Arg554His mutation in ABCD1: clinical features and genotype/phenotype correlation in female carriers 116
Preventive exercise and physical rehabilitation promote long-term potentiation-like plasticity expression in patients with multiple sclerosis 113
Interleukin-10 contrasts inflammatory synaptopathy and central neurodegenerative damage in multiple sclerosis 112
Interleukin-1β alters hebbian synaptic plasticity in multiple sclerosis 109
Inflammation and Corticospinal Functioning in Multiple Sclerosis: A TMS Perspective 109
COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab 108
Real-World 24-Month Outcomes of Ofatumumab in Relapsing Multiple Sclerosis: Efficacy, Safety, and the Impact of Frailty 106
The microRNA let-7b-5p Is Negatively Associated with Inflammation and Disease Severity in Multiple Sclerosis 106
Mood disturbances in newly diagnosed Parkinson's Disease patients reflect intrathecal inflammation 104
Genetic regulation of IL-8 influences disease presentation of multiple sclerosis 102
Preventive exercise attenuates IL-2-driven mood disorders in multiple sclerosis 97
Cost-Effectiveness Analysis of Cannabinoid Oromucosal Spray Use for the Management of Spasticity in Subjects with Multiple Sclerosis 97
Decipher non-canonical SPAST splicing mutations with the help of functional assays in patients affected by spastic paraplegia 4 (SPG4) 96
BACE1 influences clinical manifestations and central inflammation in relapsing remitting multiple sclerosis 95
Distinct intrathecal inflammatory signatures following relapse and anti-COVID-19 mRNA vaccination in multiple sclerosis 94
Interaction between miR-142-3p and BDNF Val/Met Polymorphism Regulates Multiple Sclerosis Severity 93
Interleukin 6 SNP rs1818879 Regulates Radiological and Inflammatory Activity in Multiple Sclerosis 92
Osteopontin Is Associated with Multiple Sclerosis Relapses 91
An IL-5 Single-Nucleotide Polymorphism Influences Neuroinflammation and Prospective Disease Activity in Multiple Sclerosis 90
Homeostasis of serine enantiomers is disrupted in the post-mortem caudate putamen and cerebrospinal fluid of living Parkinson's disease patients 89
Cortical plasticity in AQP4-positive NMOSD: a transcranial magnetic stimulation study 87
IL-1β contributes to neurological disability in NMOSD AQP4 + Patients 87
Multicenter Interventional Phase IV Study for the Assessment of the Effects on Patient's Satisfaction of Peg IFN Beta-1a (Pre-filled Pen) in Subjects With Relapsing-Remitting Multiple Sclerosis Unsatisfied With Other Injectable Subcutaneous Interferons (PLATINUM Study) 86
Influence of Previous Disease-Modifying Drug Exposure on T-Lymphocyte Dynamic in Patients With Multiple Sclerosis Treated With Ocrelizumab 85
Structural and Functional Assessment of the Macular Inner Retinal Layers in Multiple Sclerosis Eyes Without History of Optic Neuropathy 83
Inflammatory signature in amyotrophic lateral sclerosis predicting disease progression 82
Fatigue in Multiple Sclerosis Is Associated with Reduced Expression of Interleukin-10 and Worse Prospective Disease Activity 81
Maresin-1 promotes neuroprotection and prevents disease progression in experimental models of multiple sclerosis through metabolic reprogramming and shaping innate and adaptive disease-associated cell types 69
New variants and genotype–phenotype correlation in KIF5A mutation: the contribution of a large Italian cohort 67
Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disorders 65
Topographical Correlation between Structural and Functional Impairment of the Macular Inner Retinal Layers in Multiple Sclerosis Eyes with a History of Optic Neuropathy 63
Physical exercise modulates T cell activity and mitigates synaptic dysfunction in multiple sclerosis through vagus nerve engagement 62
MicroRNA-142-3p shuttling in extracellular vesicles marks regulatory T cell dysfunction in multiple sclerosis 58
Maresin-1 promotes neuroprotection and modulates metabolic and inflammatory responses in disease-associated cell types in preclinical models of multiple sclerosis 55
Effect of Anodal Transcranial Direct Current Stimulation on the Intensity of Post-dural Puncture Headache: Results of Two Randomized Sham Controlled Trials 53
Cladribine tablets in the new multiple sclerosis era 44
Totale 22.147
Salva come PNG Salva come JPEG
Categoria #
all - tutte 66.809
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 66.809
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022570 0 0 0 0 3 127 29 34 77 88 27 185
2022/20231.287 135 115 110 198 73 278 85 63 99 13 60 58
2023/2024531 84 20 22 29 39 118 28 40 25 26 21 79
2024/20252.201 85 427 168 93 142 216 179 103 208 267 167 146
2025/20264.081 326 182 527 270 365 132 612 475 445 309 246 192
2026/20271.638 215 225 633 552 13 0 0 0 0 0 0 0
Totale 22.147